Key Points
- Director Morgan Lee Lekstrom bought 41,000 shares on Jan. 23 at an average price of $3.13 (total ~$128,330), raising his direct stake to 48,000 shares — a 585.71% increase, as disclosed in an SEC filing.
- Biosig shares opened at $3.40 and have a 12‑month range of $0.40–$14.11, while Weiss Ratings began coverage with a "sell (d-)" and the stock carries an average analyst rating of "Sell."
Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) Director Morgan Lee Lekstrom purchased 41,000 shares of the firm's stock in a transaction on Friday, January 23rd. The stock was bought at an average cost of $3.13 per share, with a total value of $128,330.00. Following the completion of the acquisition, the director directly owned 48,000 shares of the company's stock, valued at $150,240. This trade represents a 585.71% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Biosig Technologies Price Performance
Shares of NASDAQ STEX opened at $3.40 on Tuesday. Biosig Technologies, Inc. has a 12 month low of $0.40 and a 12 month high of $14.11.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings began coverage on shares of Biosig Technologies in a research report on Friday. They issued a "sell (d-)" rating for the company. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of "Sell".
Get Our Latest Research Report on STEX
About Biosig Technologies
(
Get Free Report)
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
